Remove 2017 Remove Immune Response Remove Research
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The Merkin Prize recognizes novel technologies that have improved human health and is administered by the Broad Institute, one of the worlds leading biomedical research institutes. He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Visual Guide to Genome Editors

Codon

The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. Researchers have since discovered variants of the protein with additional useful qualities. Researchers have also discovered a slew of small Cas9s — some less than half the size of the S.

DNA
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Dive Insight: Since the FDA’s approval of Novartis’ Kymriah for leukemia in 2017, six more CAR-T therapies have reached market. These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones.

article thumbnail

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Broad Institute

Researchers from the Tumor Immunotherapy Discovery Engine ( TIDE ) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

article thumbnail

#WhyIScience Q&A: A microbiologist and immunologist finds links between our own microbes and disease mechanisms

Broad Institute

After completing his PhD in 2017, Brown joined Xavier’s lab as a postdoctoral researcher and has been at the Broad ever since, now as a staff scientist. We spoke with Brown about his experience as both a researcher and a patient in this #WhyIScience Q&A. What keeps you motivated to keep doing research?

article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).